furo<3,4-d>pyridazine-5,7-dione | 59648-15-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: furo<3,4-d>pyridazine-5,7-dione
• 英文别名: pyridiazine-4,5-dicarboxylic acid anhydride；pyridazine-4,5-dicarboxylic acid anhydride；pyridazine-4,5-dicarboxylic anhydride；furo[3,4-d]pyridazine-5,7-dione；pyridazine 4,5-dicarboxylic acid anhydride；Pyridazin-4,5-dicarbonsaeureanhydrid；Furo[3,4-d]pyridazine-5,7-dione
• CAS: 59648-15-6
• 化学式: C₆H₂N₂O₃
• 分子量: 150.093
• InChiKey: DMWJVLJVMIFAJE-UHFFFAOYSA-N

物化性质

• 熔点：
  180-190 °C (decomp)(Solv: benzene (71-43-2))
• 沸点：
  450.8±18.0 °C(Predicted)
• 密度：
  1.686±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  furo<3,4-d>pyridazine-5,7-dione 、 三苯基胍 以 四氢呋喃 为溶剂， 以97%的产率得到4-oxo-1,3-diphenyl-2-phenylimino-1,3,7,8-tetra-azaspiro<4.5>deca-6,9-diene-10-carboxylic acid
  参考文献：
  名称：

  Chimichi, Stefano; Nesi, Rodolfo; Neri, Martino, Journal of the Chemical Society. Perkin transactions I, 1984, # 11, p. 2491 - 2495

  摘要：

  DOI：
• 作为产物：
  描述：

  4,5-哒嗪二羧酸 在 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 以92%的产率得到furo<3,4-d>pyridazine-5,7-dione
  参考文献：
  名称：

  通过区域特异性置换合成6,9-双[（氨基烷基）氨基]取代的苯并[g]喹喔啉-，苯并[g]喹唑啉-和苯并[g]酞嗪-5,10-二酮

  摘要：

  6,9-二氟取代的苯并[g]喹喔啉-5,10-二酮（3A），苯并[g]喹唑啉-5,10-二酮（3B）和苯并[g]酞嗪-5,10-二酮的合成（3C）已完成。用二胺或N-（叔丁氧基羰基）乙二胺处理3A，3B或3C分别导致与2A，2B和2C有关的相应的6,9-双[（氨基烷基）氨基]取代的类似物。单取代的衍生物4h和4i可以从3A开始的位移中分离出来。嘧啶嘧啶环的竞争性开环与N，N-二甲基乙二胺反应期间发生2C。从2Ac上除去BOC保护基团得到盐酸盐2Ab。开发了一条通往6,9-二羟基苯并[g]-酞嗪-5,10-二酮（21a）的新型合成途径。容易实现21a向二甲苯磺酸酯21b的转化。用N，N-二甲基乙二胺或N-（叔丁氧基羰基）乙二胺处理21b分别导致2Ca和2Cc。从2Cc中除去BOC保护基用三氟乙酸进行离子交换，得到盐酸盐2Cb。用N-（叔丁氧基羰基）乙二胺处理二甲苯磺酸酯21b也导致单取代的类

  DOI：

  10.1002/jhet.5570300624

文献信息

• Hetero-annulated indazoles
  申请人：The University of Vermont

  公开号：US05596097A1

  公开（公告）日：1997-01-21

  This invention is directed to heteroannulated indazoles namely to 2,5-disubstituted quinolino-, isoquinolino-, phthalazino-, and quinoxalino- annulated indazole-6(2H)-ones and related mono N-oxides. These compounds have been shown to have antitumor activity.

  这项发明涉及杂环并联吲唑，特别是2,5-二取代喹啉基、异喹啉基、邻苯二氮杂环基和喹啉基并联的吲唑-6(2H)-酮及相关的单N-氧化物。这些化合物已被证明具有抗肿瘤活性。
• Ring–chain isomerism of some 4,5-disubstituted pyridazines involving heterospiro-compounds
  作者：Stefano Chimichi、Rodolfo Nesi、Mirella Scotton、Carlo Mannucci、Giorgio Adembri

  DOI：10.1039/p29800001339

  日期：——

  influenced by the nature of the solvent. A study of the behaviour of compounds (5)–(10) enabled us to establish that the spirocyclisation critically depends on both the nature of the substituents on the pyridazine ring and on the nucleophilicity of the group bonded to the phenyl ring.

  Ir，uv和1 H nmr光谱证据表明，两性离子结构（4a）最可能以固态形式存在的5-（邻氨基苯基氨基甲酰基）哒嗪-4-羧酸（4）存在于二甲基亚砜中溶液几乎完全成为3'，4'-二氢-3'-氧代螺[哒嗪5（2 ħ），2' - （1' ħ） -喹喔啉] -4-羧酸（18）。平衡（4a）⇄（18）受溶剂性质的强烈影响。对化合物（5）-（10）行为的研究使我们能够确定，螺环化主要取决于哒嗪环上取代基的性质以及与苯环键合基团的亲核性。
• ALDOSE REDUCTASE INHIBITORS AND USES THEREOF
  申请人：WASMUTH Andrew

  公开号：US20130225592A1

  公开（公告）日：2013-08-29

  The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.

  本发明涉及新型化合物及其制药组合物，以及促进皮肤健康老化、治疗皮肤疾病、治疗心血管疾病、治疗肾脏疾病、治疗血管生成障碍（如癌症）、治疗组织损伤（如非心脏组织损伤）、治疗心肌梗死发展以及使用本发明的化合物和组合物治疗其他各种疾病（如糖尿病并发症）。其他疾病可以包括但不限于动脉粥样硬化、冠状动脉疾病、糖尿病肾病、糖尿病神经病、糖尿病视网膜病变、皮肤感染、外周血管疾病、中风等。
• Aldose reductase inhibitors and uses thereof
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US11529349B2

  公开（公告）日：2022-12-20

  The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.

  本发明涉及新型化合物及其药物组合物，以及用本发明化合物和组合物促进皮肤健康老化、治疗皮肤疾病、治疗心血管疾病、治疗肾脏疾病、治疗血管生成疾病（如癌症）、治疗组织损伤（如非心脏组织损伤）、治疗不断发展的心肌梗塞以及治疗各种其他疾病（如糖尿病引起的并发症）的方法。其他疾病包括但不限于动脉粥样硬化、冠状动脉疾病、糖尿病肾病、糖尿病神经病变、糖尿病视网膜病变、皮肤感染、外周血管疾病、中风等。
• Carbon-13 nuclear magnetic resonance study of a new ring-chain tautomerism of some pyridazine derivatives
  作者：Rodolfo Nesi、Stefano Chimichi、Francesco De Sio、Mirella Scotton

  DOI：10.1002/omr.1270210111

  日期：1983.1

  AbstractThe 13C NMR spectra of a number of pyridazine derivatives have been recorded in DMSO‐d6 solution and analysed. Examination of the most diagnostic resonances, with particular emphasis on those arising from the pyridazine ring system, enabled the ready establishment of the presence of a ring‐chain tautomerism in 5‐(o‐aminophenylcarbamoyl)pyridazine‐4‐carboxylic acid, methyl 5‐(o‐aminophenylcarbamoyl)pyridazine‐4‐carboxylate, 5‐(o‐aminophenylcarbamoyl)‐3,6,‐dimethylpyridazine‐4‐carboxylic acid and 5‐(2‐amino‐1,2‐dicyanovinylenecarbamoyl)pyridazine‐4‐carboxylic acid. This gave rise to 3′,4′‐dihydro‐3′‐oxospiro[pyridazine‐5(2H),2′(1H)‐quinoxaline]‐4‐carboxylic acid, methyl 3′,4′‐dihydro‐3′oxospiro[pyridazine‐5(2H),2′(1′H)‐quinoxaline]‐4‐carboxylate, 3′,4′‐dihydro‐3′‐oxo‐3,6‐dimethylspiro[pyridazine‐5(2H), 2′(1′H)‐quinoxaline]‐4‐carboxylic acid and 5‐oxo‐2,3‐dicyano‐1,4,8,9‐tetraazaspiro[5.5]undeca‐2,7,10‐triene‐11‐carboxylic acid, respectively.